![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received for publication October 26, 2005.
Revised December 20, 2005.
Accepted for publication December 21, 2005.
Members of the aldo-keto reductase (AKR) superfamily have a broad substrate specificity in catalyzing the reduction of carbonyl-group containing xenobiotics. In the present investigation, a member of the aldose reductase subfamily, AKR1B10, was purified from human liver cytosol. This is the first time AKR1B10 has been purified in its native form. AKR1B10 showed a molecular mass of 35 kDa upon gel filtration and SDS-PAGE. Kinetic parameters for the NADPH-dependent reduction of the antiemetic 5-HT3 receptor antagonist dolasetron, the anti-tumor drugs daunorubicin and oracin, and the carcinogen 4-methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) to the corresponding alcohols have been determined by HPLC. Km-values ranged between 0.06 mM for dolasetron and 1.1 mM for daunorubicin. Enzymatic efficiencies calculated as kcat/Km were more than 100 mM-1 min-1 for dolasetron and 1.3, 0.43 and 0.47 mM-1 min-1 for daunorubicin, oracin and NNK, respectively. Thus, AKR1B10 is one of the most significant reductases in the activation of dolasetron. In addition to its reducing activity, AKR1B10 catalyzed the NADP+-dependent oxidation of the secondary alcohol (S)-1-indanol to 1-indanone with high enzymatic efficiency (kcat/Km = 112 mM-1 min-1). The gene encoding AKR1B10 was cloned from a human liver cDNA library and the recombinant enzyme was purified. Kinetic studies revealed lower activity of the recombinant compared to the native form. Immunoblot studies indicated large interindividual variations in the expression of AKR1B10 in human liver. Since carbonyl reduction of xenobiotics often leads to their inactivation, AKR1B10 may play a role in the occurrence of chemoresistance of tumors towards carbonyl-group bearing cytostatic drugs.
Key words:
antibodies, enzyme kinetics, HPLC, phase II drug metabolism
This article has been cited by other articles:
|
|
 |
|
  N. Kassner, K. Huse, H.-J. Martin, U. Godtel-Armbrust, A. Metzger, I. Meineke, J. Brockmoller, K. Klein, U. M. Zanger, E. Maser, et al. Carbonyl Reductase 1 Is a Predominant Doxorubicin Reductase in the Human Liver Drug Metab. Dispos., October 1, 2008; 36(10): 2113 - 2120. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H. Takahashi, O. S. Bains, T. A. Pfeifer, T. A. Grigliatti, R. E. Reid, and K. W. Riggs Aldo-Keto Reductase 1C2 Fails to Metabolize Doxorubicin and Daunorubicin in Vitro Drug Metab. Dispos., June 1, 2008; 36(6): 991 - 994. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Gallego, F. X. Ruiz, A. Ardevol, M. Dominguez, R. Alvarez, A. R. de Lera, C. Rovira, J. Farres, I. Fita, and X. Pares Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10 PNAS, December 26, 2007; 104(52): 20764 - 20769. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Jiang, C. Yang, H. Qu, Z. Liu, Q. S. Fu, and C. Qiao Cloning of a Novel Aldo-Keto Reductase Gene from Klebsiella sp. Strain F51-1-2 and Its Functional Expression in Escherichia coli Appl. Envir. Microbiol., August 1, 2007; 73(15): 4959 - 4965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Li, D. Zhang, L. Wang, H. Zhang, P. T. Cheng, D. Zhang, D. W. Everett, and W. G. Humphreys BIOTRANSFORMATION OF CARBON-14-LABELED MURAGLITAZAR IN MALE MICE: INTERSPECIES DIFFERENCE IN METABOLIC PATHWAYS LEADING TO UNIQUE METABOLITES Drug Metab. Dispos., May 1, 2006; 34(5): 807 - 820. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
